Dr. Clay Siegall is a science professional who has made a significant impact in the pharmaceuticals world. He acts as the CEO of the Settle Genetics, which is a renowned biotechnology company that he co-founded. The firm has majored in the development of target therapy drugs for deadly diseases such as cancer. Siegall formed Seattle Genetics in 1998, and he has assisted it in developing antibody-drug conjugates (ADCs) that have gained the approval of the FDA. The company has currently developed more than 20 different drugs by working in close collaboration with renowned drug manufacturers such as Bayer and Pfizer. Clay Siegall is also an academic scholar. He was admitted to the University of Maryland for his undergraduate studies and also has a Ph.D. in genetics, which he was awarded by the George Washington University.
Siegall has been working closely with researchers at Seattle Genetics in developing better drugs for cancer. According to him, chemotherapies have adverse effects on the human body, and they should be replaced with other less harmful cancer treatments. The company is currently increasing its drugs portfolio. Clay was motivated to establish Seattle Genetics after he developed an interest in developing cancer treatments. The firm has grown to be one of the leading drug research hubs in the United States, and it currently makes profits may selling its FDA approved drugs. The biotechnology company started making profits after holding its first IPO about a decade ago.
Clay Siegall had a successful career as a researcher before he decided to create Seattle Genetics. He was an employee of a pharmaceutical research institute that is known as Bristol-Myers Squibb, and he served it as from 1991 to 1997. Siegall worked as a senior researcher at the National Cancer Institute from 1988 to 1991. The experience that he has gained in the sector has allowed him to sit on the boards of Washington Roundtable, Alder Biopharmaceuticals, and Ultragenynx Pharmaceutical. Clay has done a lot of research and has written more than 70 publications. Most of his work is original, and he holds 15 patents for the products that he has developed at Seattle Genetics.